Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketone Esters for Drug-Resistant Epilepsy in Children
NCT05670847Phase 3Recruiting
- Sponsor
- Sohag University
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in epilepsy, sponsored by Sohag University. Primary endpoint: >= 50% reduction in seizure frequency at 28 days. Started Jan 2023; status: recruiting.
02
Drugs
(R)-3-hydroxybutyl (R)-3-hydroxybutyrate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05670847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670847.